Glaukos (GKOS) Cash from Financing Activities (2014 - 2026)
Glaukos' (GKOS) quarterly Cash from Financing Activities came in at $15.8 million in Q1 2026, up 708.67% year-on-year from $2.0 million in Q1 2025, and up 549.73% on a QoQ basis from $2.4 million in Q4 2025.
Glaukos (GKOS) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Glaukos (GKOS) has 13 years of Cash from Financing Activities data on file, last reported at $15.8 million in Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 708.67% year-over-year to $15.8 million in Q1 2026; TTM through Mar 2026 was $25.7 million, a 68.0% decrease from a year earlier, with the FY2025 full-year figure at $11.9 million, down 87.02% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $15.8 million, up from $2.4 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for GKOS reached as high as $60.1 million in Q4 2024 and fell as low as -$880000.0 in Q2 2023.
- Historically, Cash from Financing Activities has averaged $8.3 million across 5 years, with a median of $4.2 million in 2022.
- On a YoY basis, Cash from Financing Activities climbed as much as 1280.53% in 2023 and fell as far as 930.19% in 2023.
- Year by year, Cash from Financing Activities stood at $529000.0 in 2022, then soared by 1280.53% to $7.3 million in 2023, then soared by 723.13% to $60.1 million in 2024, then slumped by 95.96% to $2.4 million in 2025, then surged by 549.73% to $15.8 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $15.8 million in Q1 2026, $2.4 million in Q4 2025, and $5.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Glaukos | 8.83 Bn | 8.73 Bn | 117.23 Mn | 15.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.77 Mn |
| Mar 31, 2026 | 15.77 Mn |
| Dec 31, 2025 | 2.43 Mn |
| Dec 31, 2025 | 2.43 Mn |
| Sep 30, 2025 | 5.26 Mn |
| Sep 30, 2025 | 5.26 Mn |
| Jun 30, 2025 | 2.25 Mn |
| Jun 30, 2025 | 2.25 Mn |
| Mar 31, 2025 | 1.95 Mn |
| Mar 31, 2025 | 1.95 Mn |
| Dec 31, 2024 | 60.11 Mn |
| Dec 31, 2024 | 60.11 Mn |
| Sep 30, 2024 | 9.67 Mn |
| Sep 30, 2024 | 9.67 Mn |
| Jun 30, 2024 | 8.59 Mn |
| Jun 30, 2024 | 8.59 Mn |
| Mar 31, 2024 | 13.17 Mn |
| Mar 31, 2024 | 13.17 Mn |
| Dec 31, 2023 | 7.30 Mn |
| Dec 31, 2023 | 7.30 Mn |